ANDA 220275, held by Zydus Lifesciences. Sertraline Hydrochloride.
As of Nov 16, 2026, ANDA 220275 (Sertraline Hydrochloride), held by Zydus Lifesciences, was first approved by FDA on Jan 29, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 29, 2026 | Original application | Approved | None posted |
| Sertraline HydrochlorideEQ 150MG BASE · capsule;oral | Sertraline Hydrochloride | Rx |
| Sertraline HydrochlorideEQ 200MG BASE · capsule;oral | Sertraline Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters